semaglutide direct GLP-1 Treatment Specialist GLP-1 Weight Loss Medication -

Wegovy (semaglutide 2.4 mg) approved in the US for the treatment of MASH Novo Nordisk Novo Nordisk announced that the FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity

Aim for consistency: Make workout times part of your schedule

Experience the lightweight and easily absorbed texture of this milk serum

Coverage depends on your insurance providercontact us or your carrier to check eligibility

Fees are due at the time of service